HMGB1-Mediated Early Loss of Transplanted Islets Is Prevented by Anti–IL-6R Antibody in Mice

Objectives The limited success in achieving insulin independence of patients with type 1 diabetes mellitus after islet transplantation from a single donor, mainly due to early loss of transplanted islets, hampers clinical application of islet transplantation. Previously, we have shown in mice that the early loss of transplanted islets in the liver, the site of islet transplantation, is caused by innate immune rejection triggered by high-mobility group box 1 (HMGB1) protein released from transplanted islets. We herein determined whether the HMGB1-mediated early loss of transplanted mouse islets is prevented by anti–interleukin-6 receptor (IL-6R) antibody. Methods The effect of anti–IL-6R antibody on amelioration of hyperglycemia in streptozocin-induced diabetic mice receiving 200 islets into the liver from a single donor was evaluated in association with HMGB1-stimulated interferon-&ggr; production of hepatic mononuclear cells. Results Hyperglycemia of diabetic mice receiving 200 syngeneic islets was ameliorated with down-regulation of interferon-&ggr; production of hepatic natural killer T cells and neutrophils when anti–IL-6R was administered at the time of transplantation. This beneficial effect was also seen in allografts when alloimmune rejection was prevented by anti-CD4 antibody. Conclusions These findings demonstrate that anti–IL-6R antibody prevented the early loss of intrahepatic islet grafts with inhibiting HMGB1-induced immune activation after islet transplantation.

[1]  A. Dennison,et al.  Evation of High-Mobility Group Box 1 after Clinical Autologous Islet Transplantation and Its Inverse Correlation with Outcomes , 2014, Cell transplantation.

[2]  T. Itoh,et al.  Inhibitory Effect of Thrombomodulin on HMGB1-Stimulated IFN-γ Production of Hepatic NKT and Gr-1+ Cells, Facilitating to Prevent Early Loss of Transplanted Islets in the Liver of Mice: 1512 , 2012 .

[3]  E. Bonifacio,et al.  CXCR1/2 inhibition enhances pancreatic islet survival after transplantation. , 2012, The Journal of clinical investigation.

[4]  A. Shapiro,et al.  Update on islet transplantation. , 2012, Cold Spring Harbor perspectives in medicine.

[5]  B. Hering,et al.  Potent Induction Immunotherapy Promotes Long‐Term Insulin Independence After Islet Transplantation in Type 1 Diabetes , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  T. Itoh,et al.  Prevention of High-Mobility Group Box 1-Mediated Early Loss of Transplanted Mouse Islets in the Liver by Antithrombin III , 2012, Transplantation.

[7]  J. Singh,et al.  Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. , 2012, Clinical therapeutics.

[8]  Hiroshi Yamamoto,et al.  High-mobility group box 1 is involved in the initial events of early loss of transplanted islets in mice. , 2010, The Journal of clinical investigation.

[9]  Y. Yamashita,et al.  Prevention of Early Loss of Transplanted Islets in the Liver of Mice by Adenosine , 2009, Transplantation.

[10]  R. Larsson,et al.  Islet Surface Heparinization Prevents the Instant Blood-Mediated Inflammatory Reaction in Islet Transplantation , 2007, Diabetes.

[11]  M. Taniguchi,et al.  Successful Islet Transplantation to Two Recipients From a Single Donor by Targeting Proinflammatory Cytokines in Mice , 2007, Transplantation.

[12]  T. Kishimoto,et al.  Interleukin 6: from bench to bedside , 2006, Nature Clinical Practice Rheumatology.

[13]  L. Staudt,et al.  Clinical Trials and Observations , 2007 .

[14]  O. Ohara,et al.  Vα14 NK T cell–triggered IFN-γ production by Gr-1+CD11b+ cells mediates early graft loss of syngeneic transplanted islets , 2005, The Journal of experimental medicine.

[15]  K. Ekdahl,et al.  Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation , 2002, The Lancet.

[16]  T. Abo,et al.  Expansion of intermediate T cell receptor cells expressing interleukin-2 receptor alpha- beta+, CD8alpha+ beta+, and lymphocyte function-associated antigen-1+ in the liver in association with intrahepatic islet xenograft rejection from rat to mouse: prevention of rejection with anti-interleukin-2 re , 1997, Transplantation.

[17]  S. Akira,et al.  Interleukin-6 family of cytokines and gp130. , 1995, Blood.

[18]  R. Madhok,et al.  Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. , 1993, Annals of the rheumatic diseases.

[19]  P. Morris,et al.  ISOLATION OF RAT PANCREATIC ISLETS BY DUCTAL INJECTION OF COLLAGENASE1 , 1986, Transplantation.

[20]  J. Ono,et al.  Simple method for the collection of pancreatic islets by the use of Ficoll-Conray gradient. , 1979, Endocrinologia japonica.

[21]  P. Lacy,et al.  Transplantation of Isolated Pancreatic Islets into the Portal Vein of Diabetic Rats , 1973, Nature.

[22]  M. Taniguchi,et al.  Methods for detection, isolation and culture of mouse and human invariant NKT cells , 2007, Nature Protocols.

[23]  Ames,et al.  Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive Regimen , 2000 .

[24]  Y. Shima,et al.  Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. , 2000, Blood.

[25]  T. Kishimoto,et al.  Gp130 and the interleukin-6 family of cytokines. , 1997, Annual review of immunology.

[26]  T. Komori,et al.  Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. , 1989, Blood.